Ceruloplasmin as Redox Marker Related to Heart Failure Severity

Elżbieta Lazar-Poloczek1, Ewa Romuk2, Piotr Rozentryt3,4

  • 1Second Department of Cardiology, School of Medicine with the Division of Dentistry, Medical University of Silesia, M. C. Skłodowskiej 10 Street, 41-800 Zabrze, Poland.

Insights

Ceruloplasmin (CER) levels correlate with exercise capacity and disease severity in heart failure with reduced ejection fraction (HFrEF). Higher CER predicts poorer exercise performance, suggesting its utility as a biomarker.

Area of Science:

  • Cardiology
  • Exercise Physiology
  • Biochemistry

Background:

  • Heart failure with reduced ejection fraction (HFrEF) is a complex condition.
  • Cardiopulmonary exercise testing (CPET) is crucial for assessing functional capacity in HFrEF.
  • Biomarkers are needed to better understand disease progression and prognosis.

Purpose of the Study:

  • To investigate the relationship between ceruloplasmin (CER) levels and CPET parameters in HFrEF patients.
  • To explore correlations between CER and various clinical, inflammatory, and redox biomarkers.
  • To assess CER's predictive value for exercise capacity in HFrEF.

Main Methods:

  • A cohort of 552 HFrEF patients was analyzed.
  • Patients were classified based on Weber's classification using peak VO2.
  • Statistical analyses identified correlations and predictive variables for CER concentration.

Main Results:

  • Higher CER levels were observed in patients with lower peak VO2 (< 16 mL/kg/min) and higher VE/CO2 slope (> 45).
  • CER positively correlated with NYHA class, RV diameter, NT-proBNP, uric acid, total protein, fibrinogen, hepatic enzymes, TOS, TAC, and malondialdehyde.
  • Total oxidant status (TOS), malondialdehyde, and alkaline phosphatase independently predicted CER concentration.
  • CER was an independent predictor of peak VO2 ≤ 12 mL/kg/min.

Conclusions:

  • Ceruloplasmin is associated with impaired exercise capacity and disease severity in HFrEF.
  • CER correlates with markers of inflammation, oxidative stress, and hepatic function.
  • CER may serve as a valuable prognostic biomarker in HFrEF management.

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
265
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
104
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
418
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
74
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.0K
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
116